JP2013241424A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013241424A5 JP2013241424A5 JP2013140191A JP2013140191A JP2013241424A5 JP 2013241424 A5 JP2013241424 A5 JP 2013241424A5 JP 2013140191 A JP2013140191 A JP 2013140191A JP 2013140191 A JP2013140191 A JP 2013140191A JP 2013241424 A5 JP2013241424 A5 JP 2013241424A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- pharmaceutical composition
- composition according
- compound
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 229960005486 vaccine Drugs 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 11
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940030325 tumor cell vaccine Drugs 0.000 claims 1
- 229940023147 viral vector vaccine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71282305P | 2005-09-01 | 2005-09-01 | |
| US60/712,823 | 2005-09-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529318A Division JP2009507030A (ja) | 2005-09-01 | 2006-08-31 | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013241424A JP2013241424A (ja) | 2013-12-05 |
| JP2013241424A5 true JP2013241424A5 (enExample) | 2014-07-31 |
| JP5796040B2 JP5796040B2 (ja) | 2015-10-21 |
Family
ID=37806889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529318A Withdrawn JP2009507030A (ja) | 2005-09-01 | 2006-08-31 | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
| JP2013140191A Expired - Fee Related JP5796040B2 (ja) | 2005-09-01 | 2013-07-03 | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529318A Withdrawn JP2009507030A (ja) | 2005-09-01 | 2006-08-31 | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8715677B2 (enExample) |
| EP (2) | EP1928492B1 (enExample) |
| JP (2) | JP2009507030A (enExample) |
| AT (1) | ATE499112T1 (enExample) |
| CA (1) | CA2621136C (enExample) |
| CY (1) | CY1112325T1 (enExample) |
| DE (1) | DE602006020300D1 (enExample) |
| DK (1) | DK1928492T3 (enExample) |
| ES (2) | ES2359162T3 (enExample) |
| HR (1) | HRP20110348T1 (enExample) |
| PL (1) | PL1928492T3 (enExample) |
| RS (1) | RS51840B (enExample) |
| SI (1) | SI1928492T1 (enExample) |
| WO (1) | WO2007028047A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090068210A1 (en) * | 2007-07-09 | 2009-03-12 | Munshi Nikhil C | Immunotherapy for hematological malignancies |
| US9200253B1 (en) * | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| WO2009131730A2 (en) | 2008-01-31 | 2009-10-29 | University Of Iowa Research Foundation | IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
| US20090298882A1 (en) * | 2008-05-13 | 2009-12-03 | Muller George W | Thioxoisoindoline compounds and compositions comprising and methods of using the same |
| HRP20151366T1 (hr) | 2008-10-29 | 2016-01-15 | Celgene Corporation | Spojevi izoindolina za uporabu u lijeäśenju karcinoma |
| EP2396312A1 (en) | 2009-02-11 | 2011-12-21 | Celgene Corporation | Isotopologues of lenalidomide |
| EP3351240B1 (en) | 2009-05-19 | 2019-04-10 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| PH12012501237A1 (en) | 2009-12-22 | 2012-11-26 | Celgene Corp | (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutic uses |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CN103402980B (zh) | 2011-01-10 | 2016-06-29 | 细胞基因公司 | 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物 |
| US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| WO2012177678A2 (en) | 2011-06-22 | 2012-12-27 | Celgene Corporation | Isotopologues of pomalidomide |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES2803524T3 (es) | 2011-09-14 | 2021-01-27 | Amgen Europe Gmbh | Formulaciones de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida del ácido ciclopropanocarboxílico |
| HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| RS67339B1 (sr) | 2011-12-27 | 2025-11-28 | Amgen Europe Gmbh | Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| KR20150029678A (ko) | 2012-06-06 | 2015-03-18 | 바이오노르 이뮤노 에이에스 | 백신 |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| EP3563836A1 (en) * | 2013-03-01 | 2019-11-06 | Astex Pharmaceuticals, Inc. | Drug combinations |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9839632B2 (en) | 2013-04-02 | 2017-12-12 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| EP2801364A1 (en) * | 2013-05-07 | 2014-11-12 | Centre Hospitalier Universitaire Vaudois (CHUV) | Salmonella strain for use in the treatment and/or prevention of cancer |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2951616A1 (en) | 2014-07-11 | 2016-01-14 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
| WO2016177833A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
| TWI727211B (zh) * | 2018-09-27 | 2021-05-11 | 大江生醫股份有限公司 | 紅菽草萃取物用於提升玻尿酸合成酶之基因表現量的用途 |
| EP4173635A4 (en) * | 2020-06-26 | 2024-04-17 | Republic of Korea (Animal and Plant Quarantine Agency) | Novel immunostimulant and vaccine composition comprising same |
| CN119868399B (zh) * | 2025-03-21 | 2025-07-11 | 华南农业大学 | 杂色曲霉胞外多糖avp141-a在制备抗石斑鱼虹彩病毒的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| JP2984366B2 (ja) | 1989-04-05 | 1999-11-29 | バイオミラ、インコーポレーテッド | 免疫抑制ムチンを生成する腺がんの能動的特異免疫療法 |
| WO1993013772A1 (en) | 1992-01-21 | 1993-07-22 | Immulogic Pharmaceutical Corporation | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5728385A (en) * | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| DE69717831T3 (de) | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| ATE418536T1 (de) | 1996-08-12 | 2009-01-15 | Celgene Corp | Neue immunotherapeutische mittel und deren verwendung in der reduzierung von cytokinenspiegel |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| CZ299253B6 (cs) | 1998-03-16 | 2008-05-28 | Celgene Corporation | Isoindolinový derivát, jeho použití pro výrobu léciva a farmaceutická kompozice tento derivát obsahující |
| CZ20013338A3 (cs) | 1999-03-18 | 2002-03-13 | Celgene Corporation | Substituované 1-oxo-a l,3-dioxoisoindoliny a jejich pouľití ve farmaceutických prostředcích pro sníľení koncentrací zánětlivých cytokinů |
| WO2001045750A1 (en) * | 1999-12-21 | 2001-06-28 | The Regents Of The University Of California | Method for preventing an anaphylactic reaction |
| AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030129161A1 (en) * | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
| CN1662251B (zh) * | 2002-04-19 | 2012-10-10 | 恩多塞特公司 | 佐剂增强的免疫应用 |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CA2672000C (en) * | 2002-05-17 | 2011-11-29 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma |
| CA2501940A1 (en) * | 2002-10-09 | 2004-04-22 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| EP1596871A4 (en) * | 2003-02-28 | 2006-08-23 | Drew M Pardoll | T-CELL REGULATION |
| US20050048054A1 (en) * | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
-
2006
- 2006-08-31 US US11/514,447 patent/US8715677B2/en not_active Expired - Fee Related
- 2006-08-31 DE DE602006020300T patent/DE602006020300D1/de active Active
- 2006-08-31 SI SI200631013T patent/SI1928492T1/sl unknown
- 2006-08-31 EP EP06824878A patent/EP1928492B1/en active Active
- 2006-08-31 AT AT06824878T patent/ATE499112T1/de active
- 2006-08-31 HR HR20110348T patent/HRP20110348T1/hr unknown
- 2006-08-31 ES ES06824878T patent/ES2359162T3/es active Active
- 2006-08-31 RS RS20110194A patent/RS51840B/sr unknown
- 2006-08-31 WO PCT/US2006/034271 patent/WO2007028047A2/en not_active Ceased
- 2006-08-31 DK DK06824878.0T patent/DK1928492T3/da active
- 2006-08-31 EP EP11151126.7A patent/EP2301535B1/en active Active
- 2006-08-31 CA CA2621136A patent/CA2621136C/en not_active Expired - Fee Related
- 2006-08-31 PL PL06824878T patent/PL1928492T3/pl unknown
- 2006-08-31 JP JP2008529318A patent/JP2009507030A/ja not_active Withdrawn
- 2006-08-31 ES ES11151126.7T patent/ES2485316T3/es active Active
-
2011
- 2011-04-13 CY CY20111100376T patent/CY1112325T1/el unknown
-
2012
- 2012-04-02 US US13/437,739 patent/US20120190110A1/en not_active Abandoned
-
2013
- 2013-07-03 JP JP2013140191A patent/JP5796040B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013241424A5 (enExample) | ||
| JP2009507030A5 (enExample) | ||
| SA519402405B1 (ar) | مركبات مثبط فيروس نقص المناعة البشري | |
| JP2016515561A5 (enExample) | ||
| EA202090530A1 (ru) | Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич | |
| JP2012087150A5 (enExample) | ||
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| JP2015187156A5 (enExample) | ||
| WO2015061294A8 (en) | Use of sting agonists to treat chronic hepatitis b virus infection | |
| JP2019526596A5 (enExample) | ||
| JP2016531144A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2015524462A5 (enExample) | ||
| EA201301158A1 (ru) | Противовирусные соединения | |
| HRP20110348T1 (hr) | Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| NI201600048A (es) | Formulaciones de (s)- 3- (4-((4-(morfolinometil) bencil)oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona | |
| EP3439696A4 (en) | THERAPEUTIC VACCINE AGAINST THE HEPATITIS B VIRUS (HBV) USING THE HBV CORE ANTIGEN | |
| EA201892746A1 (ru) | Лечение гематологической злокачественной опухоли с помощью 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
| JP2015098469A5 (enExample) | ||
| MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
| JP2015522522A5 (enExample) | ||
| JP2016539157A5 (enExample) | ||
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| MX387639B (es) | Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base. |